Vertex Pharmaceuticals
VRTX
505.64
+3.33
+0.66%
Vertex Pharmaceuticals
US · VRTX
#155 by market cap
Listed 1970
505.64
+3.33
+0.66%
Live - 5344 symbols - heartbeat 26s ago
· 2026-10-08 08:19
Pre-market
506.67
+0.20%
After-hours
505.80
+0.03%
Overnight
505.01
-0.12%
- Market cap
- 128.16B
- P/E (TTM)i
- 29.45
- P/Bi
- 6.33
- EPSi
- 15.32
- Div yieldi
- 0.00%
- 52W posi
- 65%
Reader sentiment
Are you bullish or bearish on VRTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 5 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.1 percentage points.
Institutional ownership
- Held by institutions
- 97.25% -0.11pp
- Institutions
- 2,113 -5
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions trimmed shares last reporting period, and the stock has seen net inflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund86.80%
Public Company3.21%
Hedge Fund1.93%
Government Pension Fund1.88%
Private Company1.40%
Sovereign Wealth Fund1.26%
Insurance Company0.30%
Individual/Insider0.20%
Family Office/Trust0.18%
Other2.83%
Top holders as of 2026-06-30
Capital Research
20.05% · 50.81M sh
BlackRock
9.51% · 24.11M sh
Vanguard Capital Management, LLC
7.10% · 18.01M sh
State Street Global Advisors
4.68% · 11.87M sh
Invesco Capital Management LLC
2.93% · 7.43M sh
Other
55.72%
Geode Capital Management, LLC
2.37% · 6.02M sh
J.P. Morgan Asset Management, Inc.
2.12% · 5.38M sh
Vanguard Portfolio Management, LLC
1.92% · 4.88M sh
Loomis, Sayles & Company L.P.
1.55% · 3.92M sh
UBS Asset Management
1.50% · 3.80M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 25 buys · 25 sells
| Name | Role | Stake |
|---|---|---|
| Amit Sachdev | Executive VP & Chief Patient Officer | 0.03% |
| Stuart Arbuckle | Chief Operating Officer | 0.03% |
| Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | 0.02% |
| Reshma Kewalramani | Chief Executive Officer | 0.02% |
| Bruce Sachs | Lead Independent Director | 0.02% |
| Jeffrey Leiden | Executive Chairperson | 0.01% |
| David Altshuler | Executive VP of Global Research & Chief Scientific Officer | 0.01% |
| Charles Wagner | Chief Financial Officer | 0.01% |
| Joy Liu | Corporate Secretary | 0.01% |
| Edward Atkinson | EVP, Chief Technical Operations Officer & Head of Biopharmaceutical Sciences and Manufacturing Ops. | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-07 | Jasper van Grunsven | Executive VP & Chief Pain & New Product Planning Officer | Other Acquisition | +8,682 | -- |
| 2026-08-27 | Kristen Ambrose | Chief Accounting Officer | Other Acquisition | +5,000 | -- |
| 2026-08-26 | Bruce Sachs | Lead Independent Director | Other Disposition | -6,000 | -- |
| 2026-07-20 | Amit Sachdev | Executive VP & Chief Patient Officer | Other Acquisition | +8,251 | -- |
| 2026-07-20 | Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | Other Acquisition | +8,251 | -- |
| 2026-07-14 | Bruce Sachs | Lead Independent Director | Other Derivative Acquisition | +99 | -- |
| 2026-07-14 | Alan Garber | Independent Director | Other Derivative Acquisition | +31 | -- |
| 2026-07-01 | Ourania Tatsis | Executive VP and Chief Regulatory & Quality Officer | Automatic Disposition | -1,500 | $524.99 |
| 2026-07-01 | Duncan McKechnie | Senior VP & Head of North America Commercial | Automatic Disposition | -1,541 | $519.00 |
| 2026-06-30 | Joy Liu | Corporate Secretary | Automatic Disposition | -828 | $502.71 |
| 2026-06-25 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -596 | $482.50 |
| 2026-06-17 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,020 | $462.17 |
| 2026-06-14 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -4,062 | $450.00 |
| 2026-06-04 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,745 | $450.00 |
| 2026-05-31 | Joy Liu | Corporate Secretary | Automatic Disposition | -828 | $439.91 |
| 2026-05-28 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,974 | $450.00 |
| 2026-05-14 | Mark Bunnage | Senior VP & Head of Research | Automatic Disposition | -33 | $453.45 |
| 2026-05-14 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -1,354 | $453.45 |
| 2026-05-11 | Carmen Bozic | Executive VP of Global Medicines Development & Medical Affairs and Chief Medical Officer | Automatic Disposition | -6,988 | $450.00 |
| 2026-05-05 | Jonathan Biller | Chief Legal Officer | Intent to Sell (Form 144) | -5,193 | $424.25 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:19:31 · For reference only, not investment advice and not tailored to your situation.